Heparin-induced thrombocytopenia and thrombosis syndrome:: in vivo cross-reactivity with danaparoid and successful treatment with r-Hirudin

被引:31
作者
Keng, TB [1 ]
Chong, BH [1 ]
机构
[1] Prince Wales Hosp, Dept Haematol, Randwick, NSW 2031, Australia
关键词
danaparoid; r-Hirudin; heparin; thrombocytopenia; HITTS;
D O I
10.1046/j.1365-2141.2001.02943.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Heparin-induced thrombocytopenia and thrombosis syndrome (HITTS) is an immune-mediated drug reaction that occurs 5-14 d after initiation of heparin therapy and is a potentially life-threatening thrombotic complication. The antibody-heparin-PF4 complexes cause platelet activation and generation of platelet microparticles. The need for anticoagulant treatment in asymptomatic thrombocytopenia. is uncertain. However, treatment is warranted In HITTS, as illustrated in the case reported here. Danaparoid, r-Hirudin and argatroban are effective drugs. Danaparoid has a 10-50% in vitro cross-reactivity rate with the HIT antibodies, but has been proven to be clinically efficacious even in these cases, Here, we report a case of in vivo cross-reactivity with danaparoid, the patient showed an excellent recovery with r-Hirudin.
引用
收藏
页码:394 / 396
页数:3
相关论文
共 36 条
  • [1] Persistent heparin-induced thrombocytopenia: danaparoid cross-reactivity or delayed-onset heparin-induced thrombocytopenia? A case report
    Horlait, Geoffrey
    Minet, Valentine
    Mullier, Francois
    Michaux, Isabelle
    BLOOD COAGULATION & FIBRINOLYSIS, 2017, 28 (02) : 193 - 197
  • [2] Heparin-induced thrombocytopenia and the use of r-hirudin during cardiopulmonary bypass
    Manikappa, S
    Benfield, K
    Gan, TE
    Butler, J
    Malan, E
    Tran, HAM
    Tucker, A
    ANAESTHESIA AND INTENSIVE CARE, 2005, 33 (03) : 388 - 392
  • [3] Danaparoid for heparin-induced thrombocytopenia: an analysis of treatment failures
    Kodityal, S
    Manhas, AH
    Udden, M
    Rice, L
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2003, 71 (02) : 109 - 113
  • [4] In vitro cross-reactivity of danaparoid sodium in patients with heparin-induced thrombocytopenia type II undergoing cardiovascular surgery
    Koster, A
    Meyer, O
    Hausmann, H
    Kuppe, H
    Hetzer, R
    Mertzlufft, F
    JOURNAL OF CLINICAL ANESTHESIA, 2000, 12 (04) : 324 - 327
  • [7] Successful treatment of heparin-induced thrombocytopenia (HIT) type II in childhood with recombinant hirudin
    Schiffmann, H
    Unterhalt, M
    Harms, K
    Figulla, HR
    Volpel, H
    Greinacher, A
    MONATSSCHRIFT KINDERHEILKUNDE, 1997, 145 (06) : 606 - 612
  • [9] HEPARIN-INDUCED THROMBOCYTOPENIA AND THROMBOSIS - A POTENTIAL FATAL COMPLICATION IN A ROUTINE TREATMENT
    BOON, DMS
    KAPPERSKLUNNE, MC
    MICHIELS, JJ
    STIBBE, J
    VANVLIET, HHDM
    NETHERLANDS JOURNAL OF MEDICINE, 1995, 46 (03) : 146 - 152
  • [10] Cross-reactivity study of low molecular weight heparins and heparinoid in heparin-induced thrombocytopenia
    Vun, CM
    Evans, S
    Chong, BH
    THROMBOSIS RESEARCH, 1996, 81 (05) : 525 - 532